Rocket Pharmaceuticals, Inc. (RCKT)
2.385
-0.05
(-2.05%)
USD |
NASDAQ |
Nov 06, 16:00
2.385
0.00 (0.00%)
After-Hours: 20:00
Rocket Pharmaceuticals Research and Development Expense (Quarterly) : 28.22M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 28.22M |
| March 31, 2026 | 30.17M |
| December 31, 2025 | 28.04M |
| September 30, 2025 | 32.55M |
| June 30, 2025 | 41.04M |
| March 31, 2025 | 34.08M |
| December 31, 2024 | 35.88M |
| September 30, 2024 | 40.79M |
| June 30, 2024 | 44.79M |
| March 31, 2024 | 43.76M |
| December 31, 2023 | 40.45M |
| September 30, 2023 | 45.08M |
| June 30, 2023 | 50.20M |
| March 31, 2023 | 45.23M |
| December 31, 2022 | 48.98M |
| September 30, 2022 | 42.29M |
| June 30, 2022 | 40.30M |
| March 31, 2022 | 29.97M |
| December 31, 2021 | 28.98M |
| September 30, 2021 | 39.18M |
| June 30, 2021 | 24.10M |
| March 31, 2021 | 27.87M |
| December 31, 2020 | 50.41M |
| September 30, 2020 | 21.36M |
| June 30, 2020 | 16.61M |
| Date | Value |
|---|---|
| March 31, 2020 | 16.84M |
| December 31, 2019 | 14.56M |
| September 30, 2019 | 15.13M |
| June 30, 2019 | 13.99M |
| March 31, 2019 | 14.89M |
| December 31, 2018 | 23.67M |
| September 30, 2018 | 13.06M |
| June 30, 2018 | 10.77M |
| March 31, 2018 | 5.743M |
| December 31, 2017 | 4.918M |
| September 30, 2017 | 4.894M |
| June 30, 2017 | 2.819M |
| March 31, 2017 | 2.285M |
| December 31, 2016 | 9.493M |
| September 30, 2016 | 8.412M |
| June 30, 2016 | 6.465M |
| March 31, 2016 | 7.615M |
| December 31, 2015 | 5.919M |
| September 30, 2015 | 3.612M |
| June 30, 2015 | 1.954M |
| March 31, 2015 | 1.069M |
| December 31, 2014 | 0.937M |
| September 30, 2014 | 1.243M |
| June 30, 2014 | 1.862M |
| March 31, 2014 | 1.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 82.55M |
| Intellia Therapeutics, Inc. | 81.42M |
| Beam Therapeutics, Inc. | 110.11M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |
| Oncolytics Biotech, Inc. | 4.262M |